Serum lipids and apolipoproteins in Greek postmenopausal women: Association with estrogen, estrogen-progestin, tibolone and raloxifene therapy Authors
First Online: 18 March 2014 Accepted: 14 February 2003 DOI:
Cite this article as: Creatsas, G., Christodoulakos, G., Lambrinoudaki, I. et al. J Endocrinol Invest (2003) 26: 545. doi:10.1007/BF03345218 Abstract
The aim of this study was to assess lipid and apolipoprotein levels in postmenopausal women taking various regimens of replacement therapy or no therapy. Seven hundred forty-eight postmenopausal women followed in the Menopause Clinic of the 2
nd Department of Obstetrics and Gynecology, University of Athens, Aretaieion Hospital, were studied in a cross-sectional design. Women were either non-users of replacement therapy (no.=511) or users of one of the following regimens: conjugated equine estrogen 0.625 mg (CEE, no.=34), CEE 0.625 mg plus medroxyprogesterone acetate 5 mg (CEE/MPA, no.=60), 17β-estradiol 2 mg plus norethisterone acetate 1 mg (E 2/NETA, no.=44), tibolone 2.5 mg (no.=84), raloxifene HCl 60 mg (no.=51). Total cholesterol (TC), LDL-cholesterol (LDL-C) and HDL-cholesterol (HDL-C), triglycerides (TG), apolipoprotein A 1 (ApoA 1) and apolipoprotein B (ApoB) levels were assessed. Women were grouped according to replacement regimen and mean levels of lipid and apolipoproteins were compared between groups. Women in the raloxifene group were older and longer menopaused. After adjustment for age and duration of menopause, TG levels were significantly lower in the tibolone and E 2/NETA groups (75 and 89.9 mg/dl, respectively) compared to non-users. TC was lower in all therapy groups, but the difference acquired significance only in the E 2/NETA (207.8 mg/dl), compared to non-users (231.5 mg/dl). LDLC levels were significantly lower in the CEE (133.8 mg/dl), CEE/MPA (130.4 mg/dl) and raloxifene group (129.9 mg/dl) compared to non-users (151.9 mg/dl). There was no difference in HDL-C levels between users and non-users (58.9 mg/dl) except for the tibolone group where HDL-C was significantly lower (48.6 mg/dl). ApoA 1 levels were significantly higher in the CEE/MPA group (194.4 mg/dl) and significantly lower in the tibolone group (141.6 mg/dl) compared to non-users (170.4 mg/dl). No difference was detected between groups concerning ApoB levels. In conclusion, tibolone therapy is associated with lower TG levels as well as lower HDL and ApoA1 levels. ERT, continuous combined estrogen-progestin therapy (HRT) and raloxifene are associated with lower LDL-C levels. Among continuous combined HRT users, CEE/MPA is associated with higher ApoA 1 levels, while E 2/NETA with lower TG levels. Large prospective randomized studies are required to validate these results. Key-words ERT HRT tibolone raloxifene lipids apolipoproteins References
Nazr A, Breckwoldt M. Estrogen replacement therapy and cardiovascular protection: lipid mechanisms are the tip of the iceberg. Gynecol Endocrinol 1998, 12: 43–59.
Chen FP, Lee N, Wang CH, Cherng WJ, Soong YK. Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women. Fertil Steril 1998, 69: 267–73.
Sitruk-Ware R. Progestins and cardiovascular risk markers. Steroids 2000, 65: 651–8.
Ylikorkala O, Lim P, Caubel P. Effects on serum lipid profiles of continuous 17β-estradial, intermittent norgestimate regimens versus continuous combined 17β-estradiol/norethisterone acetate hormone replacement therapy. Clin Ther 2000, 22: 622–6.
Kojima K, Abe-Dohmae S, Arakawa R, Murakami I, Suzumori K, Yokoyama S. Progesterone inhibits apolipoprotein-mediated cellular lipid release: a putative mechanism for the decrease of high-density lipoprotein. Biochim Biophys Acta 2001, 1532: 173–84.
Crook D. Lipid predictors of coronary heart disease and tibolone users. Eur Heart J 2001, 3 (Suppl M): M22–6.
Itoi H, Minakami H, Iwasaki R, Sato I. Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen on serum lipid profile in early postmenopausal women. Maturitas 2000, 36: 217–22.
Stevenson JC. Are changes in lipoproteins during HRT important? Br J Obstet Gynecol 1996, 103 (Suppl 13): 39–44.
Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999, 340: 1801–11.
Mijatovic V, van der Mooren MJ, Stehouer CD, Netelenbos JC, Kenemans P. Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection. Gynecol Endocrinol 1999, 13: 130–44.
Creatsas GC, Malamitsi-Puchner AB, Hassan EA, Economou EB, Aravantinos DI. Endothelin plasma levels in primary amenorrheic adolescents before and after estrogen treatment. J Soc Gynecol Investing 1996, 3: 350–3.
Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998, 280: 605–13.
Petitti DB. Editorial: Hormone replacement therapy for prevention. More evidence, more pessimism. JAMA 2002, 288: 1.
The Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002, 288: 321–33.
Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and alipoprotein (a) concentrations: analysis of studies published from 1974–2000. Fertil Steril 2001, 75: 898–915.
Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks and benefits. Menopause 2002, 9: 6–15.
Von Eckardstein A, Schmiddem K, Hovels A, et al. Lowering of HDL cholesterol in postmenopausal women by tibolone is not associated with changes in cholesterol efflux capacity or paraoxonase activity. Atherosclerosis 2001, 159: 433–9.
Mendoza N, Suarez AM, Alamo F, Bartual E, Vergara F, Herruzo A. Lipid effects, effectiveness and acceptability of tibolone versus transdermic 17β-estradiol for hormonal replacement therapy in women with surgical menopause. Maturitas 2000, 37: 37–43.
Williams JK, Hall J, Anthony MS, Register TC, Reis SE, Clarkson TB. A comparison of tibolone and hormone replacement therapy on coronary artery and myocardial function in ovariectomized atherosclerotic monkeys. Menopause 2002, 9: 41–51.
Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998, 279: 1445–51.
Nickelsen T, Creatsas G, Rechberger T, et al. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study. Climacteric 2001, 4: 320–31.
Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997, 337: 1641–7.
Prelevic GM, Kwong P, Byrne DJ, Jagroop JA, Ginsburg J, Mikhailidis DP. A cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 2002, 77: 945–51.
Sanada M, Nakagawa H, Kodama I, Sakasita T, Ohama K. Three-year study of estrogen alone versus combined with progestin in postmenopausal women with or without hypercholesterolemia. Metabolism 2000, 49: 784–9.
Ossewaarde ME, Bots ML, Bak AA, et al. Effect of hormone replacement therapy on lipids in perimenopausal and early postmenopausal women. Maturitas 2001, 39: 209–16.
Castelo-Branco C, Casals E, Figueras F, et al. Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins A
and B. Menopause 1999, 6: 92–7.
Erenus M, Karakoc B, Gurler A. Comparison of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance. Climacteric 2001, 4: 228–34.
Baracat EC, Barbosa IC, Giordano MG, et al. A randomised, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects of symptom control, bleeding pattern, lipid profile and tolerability. Climacteric 2002, 5: 60–9.
Barnes JF, Farish E, Rankin M, Hart DM. A comparison of the effects of 2 continuous HRT regimens on cardiovascular risk factors. Atherosclerosis 2002, 160: 185–93.
Jackson G. Tibolone and the cardiovascular system. Eur Heart J 2001, 3 (Suppl M): M17–21.
Bjarnason NH, Bjarnason K, Haarbo J, Bennink HJ, Christiansen C. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 1997, 82: 1752–6.
Zandberg P, Peters JLM, Demacker PN, de Reeder EG, Smit MJ, Meuleman DG. Comparison of the antiatherosclerotic effect of tibolone with that of estradiol and ethinyl estradiol in cholesterol-fed, ovariectomized rabbits. Menopause 2001, 8: 96–105.
Von Eckardstein A, Crook D, Elbers J, et al. Tibolone lowers high density lipoprotein cholesterol by increasing hepatic lipase activity but does not impair cholesterol efflux. Clin Endocrinol (Oxf) 2003, 58: 49–58.
Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. Four year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002, 287: 847–57.
Blum A, Cannon RO 3rd. Selective estrogen receptor modulator effects on serum lipoproteins and vascular function in postmenopausal women and hypercholesterolemic men. Ann NY Acad Sci 2001,949: 168–74.
Johnston CC, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover and serum lipid levels in early postmenopausal women: three-year data from 2 double blind randomized placebocontrolled trials. Arch Int Med 2000,160: 3444–50.
Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis and vascular function. Cardiovasc Res. 2002, 53: 605–19.
PubMed CrossRef Copyright information
© Italian Society of Endocrinology (SIE) 2003